The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial
Open accessAbstract
BACKGROUND: Dalazatide is a specific inhibitor of the Kv1.3 potassium channel. The expression and function of Kv1.3 channels are required for the function of chronically activated memory T cells, which have been shown to be key mediators of autoimmune diseases, including psoriasis. OBJECTIVE: The primary objective was to evaluate the safety of repeat doses of dalazatide in adult patients with mild-to-moderate plaque psoriasis. Secondary objectives were to evaluate clinical proof of concept and the effects of dalazatide on mediators of inflammation in the blood and on chronically activated memory T cell populations. METHODS: Patients (n = 24) were randomized 5:5:2 to receive dalazatide at 30 mcg/dose, 60 mcg/dose, or placebo twice weekly by subcutaneous injection (9 doses total). Safety was assessed on the basis of physical and neurological examination and laboratory testing. Clinical assessments included body-surface area affected, Psoriasis Area and Severity Index (PASI), and investigator and patient questionnaires. RESULTS: The most common adverse events were temporary mild (Grade 1) hypoesthesia (n = 20; 75% placebo, 85% dalazatide) and paresthesia (n = 15; 25% placebo, 70% dalazatide) involving the hands, feet, or perioral area. Nine of 10 patients in the 60 mcg/dose group had a reduction in their PASI score between baseline and Day 32, and the mean reduction in PASI score was significant in this group (P < 0.01). Dalazatide treatment reduced the plasma levels of multiple inflammation markers and reduced the expression of T cell activation markers on peripheral blood memory T cells. LIMITATIONS: The study was small and drug treatment was for a short duration (4 weeks). CONCLUSION: This study indicates that dalazatide is generally well tolerated and can improve psoriatic skin lesions by modulating T cell surface and activation marker expression and inhibiting mediators of inflammation in the blood. Larger studies of longer duration are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the only class of Kv1.3 channel blockers that has successfully completed phase Ib studies in humans for psoriasis (ShK analogs) has not been tested in pre-clinical models of AD pathology [53, 54].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“ShK-223 was selected due to its improved stability and > 10,000-fold selectivity for Kv1.3 channels over neuronal Kv channels [53, 54].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Experimental — accuracy not yet measuredIn the citing paper
“Our pre-clinical findings using ShK-223 are of translational importance because a Kv1.3-blocking ShK analog (dalazatide or ShK-186) that is very similar to ShK-223, is the only selective Kv1.3 blocker to have successfully completed early phase human studies for systemic autoimmunity [53].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schweiger, D., Baufeld, C., Drescher, P., Oltrogge, B., Höpfner, S., Mess, A., Lüttke, J., Rippke, F., Filbry, A., & Max, H. (2013) · Skin Pharmacology and Physiology · doi:10.1159/000348473 · Cited by 1,346
Arican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005) · Mediators of Inflammation · doi:10.1155/mi.2005.273 · Cited by 805
Psoriasis prevalence among adults in the United States
Rachakonda, T. D., Schupp, C. W., & Armstrong, A. W. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.11.013 · Cited by 783
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5857 · Cited by 597
Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes
Ellis, C. N., & Krueger, G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450403 · Cited by 582
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Lim, H. W., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.027 · Cited by 558
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605136103 · Cited by 538
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Resident memory T cells in human health and disease
Clark, R. A. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010641 · Cited by 446
The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS
Wulff, H., Calabresi, P. A., Allie, R., Yun, S., Pennington, M., Beeton, C., & Chandy, K. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16921 · Cited by 422
Armstrong, A. W., Robertson, A. D., Wu, J., Schupp, C., & Lebwohl, M. G. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.5264 · Cited by 386
Castañeda, O., Sotolongo, V., Amor, A. M., Stöcklin, R., Anderson, A. J., Harvey, A. L., Engström, Å., Wernstedt, C., & Karlsson, E. (1995) · Toxicon · doi:10.1016/0041-0101(95)00013-c · Cited by 283
CD40 and autoimmunity: The dark side of a great activator
Peters, A. L., Stunz, L. L., & Bishop, G. A. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.05.012 · Cited by 270
Bautista, D. M., Sigal, Y. M., Milstein, A. D., Garrison, J. L., Zorn, J. A., Tsuruda, P. R., Nicoll, R. A., & Julius, D. (2008) · Nature Neuroscience · doi:10.1038/nn.2143 · Cited by 258
Spuls, P. I., Lecluse, L. L. A., Poulsen, M.-L. N. F., Bos, J. D., Stern, R. S., & Nijsten, T. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.391 · Cited by 245
Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability
Witt, K. A., Gillespie, T. J., Huber, J. D., Egleton, R. D., & Davis, T. P. (2001) · Peptides · doi:10.1016/s0196-9781(01)00537-x · Cited by 227
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases
Chi, V., Pennington, M. W., Norton, R. S., Tarcha, E. J., Londono, L. M., Sims-Fahey, B., Upadhyay, S. K., Lakey, J. T., Iadonato, S., Wulff, H., et al. (2012) · Toxicon · doi:10.1016/j.toxicon.2011.07.016 · Cited by 213
Self-citationClinical improvement in psoriasis with specific targeting of interleukin-23
Kopp, T., Riedl, E., Bangert, C., Bowman, E. P., Greisenegger, E., Horowitz, A., Kittler, H., Blumenschein, W. M., McClanahan, T. K., Marbury, T., et al. (2015) · Nature · doi:10.1038/nature14175 · Cited by 210
Matheu, M. P., Beeton, C., Garcia, A., Chi, V., Rangaraju, S., Safrina, O., Monaghan, K., Uemura, M. I., Li, D., Pal, S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.07.015 · Cited by 196
Wulff, H., Knaus, H.-G., Pennington, M., & Chandy, K. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.776 · Cited by 194
Topical treatments for chronic plaque psoriasis
Mason, A. R., Mason, J., Cork, M., Dooley, G., & Hancock, H. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005028.pub3 · Cited by 194
Campa, M., Mansouri, B., Warren, R. B., & Menter, A. (2015) · Dermatology and Therapy · doi:10.1007/s13555-015-0092-3 · Cited by 144
Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease
Chandy, K. G., & Norton, R. S. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.02.015 · Cited by 134
Autoimmune effector memory T cells: the bad and the good
Devarajan, P., & Chen, Z. (2013) · Immunologic Research · doi:10.1007/s12026-013-8448-1 · Cited by 121
Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro.
Schulz, B., Michel, G., Wagner, S. N., Süss, R., Beetz, A., Peter, R. U., Kemény, L. V., & Ruzicka, T. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.8.4399 · Cited by 120
Tarcha, E. J., Chi, V., Muñoz-Elías, E. J., Bailey, D., Londono, L. M., Upadhyay, S. K., Norton, K., Banks, A., Tjong, I., Nguyen, H., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.191890 · Cited by 117 · cited 1×
“In contrast, dalazatide, like other peptide drugs, is not readily distributed across the intact blood-brain barrier [38, 39] Several factors in this study impacted the assessment of clinical responsiveness, primarily low baseline BSA and patient bodyweight.”
BackgroundSelf-citationPsoriasis: from pathogenesis to novel therapeutic approaches
Monteleone, G., Pallone, F., MacDonald, T. T., Chimenti, S., & Costanzo, A. (2010) · Clinical Science · doi:10.1042/cs20100163 · Cited by 117
4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review
Jensen, H. B., Ravnborg, M. H., Dalgas, U., & Stenager, E. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613512712 · Cited by 117
Systematic Review of UV-Based Therapy for Psoriasis
Almutawa, F., Alnomair, N., Wang, Y., Hamzavi, I. H., & Lim, H. W. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0015-y · Cited by 114
Chiang, E. Y., Li, T., Jeet, S., Peng, I., Zhang, J., Lee, W. P., DeVoss, J., Caplazi, P., Chen, J., Warming, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14644 · Cited by 108
Analogs of the Sea Anemone Potassium Channel Blocker ShK for the Treatment of Autoimmune Diseases
Beeton, C., Pennington, M. W., & Norton, R. S. (2011) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152811797200641 · Cited by 99
Hu, L., Pennington, M. W., Jiang, Q., Whartenby, K. A., & Calabresi, P. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4563 · Cited by 90
Physiological Basis of Tingling Paresthesia Evokedby Hydroxy-α-Sanshool
Lennertz, R. C., Tsunozaki, M., Bautista, D. M., & Stucky, C. L. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4666-09.2010 · Cited by 87
Miyadera, H., & Tokunaga, K. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.100 · Cited by 87
Gocke, A. R., Lebson, L. A., Grishkan, I. V., Hu, L., Nguyen, H. M., Whartenby, K. A., Chandy, K. G., & Calabresi, P. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103095 · Cited by 75
Toxins Targeting the KV1.3 Channel: Potential Immunomodulators for Autoimmune Diseases
Zhao, Y., Huang, J., Yuan, X., Peng, B., Liu, W., Han, S. H., & He, X. (2015) · Toxins · doi:10.3390/toxins7051749 · Cited by 58
Voltage-Gated Ion Channels as Drug Targets
(2006) · Methods and principles in medicinal chemistry · doi:10.1002/3527608141 · Cited by 41
Hsiao, C., Kaur, G., Vong, A., Bawa, H., & Chandler, S. H. (2009) · Journal of Neurophysiology · doi:10.1152/jn.91053.2008 · Cited by 40
Combined Use of Systemic Agents for Psoriasis
Busard, C. I., Zweegers, J., Limpens, J., Langendam, M. W., & Spuls, P. I. (2014) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.1111 · Cited by 36
Circulating CLA + T lymphocytes as peripheral cell biomarkers in T ‐cell‐mediated skin diseases
Ferrán, M., Ruiz‐Romeu, E., Rincón, C., Sagristà, M., Giménez‐Arnau, A. M., Celada, A., Pujol, R. M., Holló, P., Jókai, H., & Santamaria‐Babí, L. F. (2013) · Experimental Dermatology · doi:10.1111/exd.12154 · Cited by 34
Safety and Tolerability of Tumor Necrosis Factor-α Inhibitors in Psoriasis: A Narrative Review
Semble, A. L., Davis, S., & Feldman, S. R. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0053-5 · Cited by 33
The CNS under pathophysiologic attack—examining the role of K2P channels
Ehling, P., Cerina, M., Budde, T., Meuth, S. G., & Bittner, S. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1664-2 · Cited by 32
Topical treatments for chronic plaque psoriasis
Mason, A., Mason, J. M., Cork, M. J., Dooley, G., & Edwards, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005028 · Cited by 18
Clinical overview of the seizure risk of dalfampridine
Haut, S. R., Bienen, E. J., & Miller, A. E. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.697896 · Cited by 16
Kv1.3 Potassium Channel: Physiology, Pharmacology and Therapeutic Indications
Chandy, K. G., Wulff, H., Beeton, C., Calabresi, P. A., Gutman, G. A., & Pennington, M. W. (2006) · Methods and principles in medicinal chemistry · doi:10.1002/3527608141.ch7b · Cited by 11
Alefacept: where it stands today
Chaarani, J., & Lebwohl, M. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003641967 · Cited by 9
Alefacept treatment for chronic plaque psoriasis.
Dunn, L. K., & Feldman, S. R. (2010) · PubMed · Cited by 6
Distribution of the 4-aminopyridine derivative 3-methoxy-4-aminopyridime in mice
Berger, S. G., Waser, P. G., & Sin‐Ren, A. C. (1989) · Neuropharmacology · doi:10.1016/0028-3908(89)90056-7 · Cited by 5
Cited by
Rangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0254-8 · Cited by 430
“3 channels over neuronal Kv channels [53, 54].”
BackgroundSchendel, V., Rash, L. D., Jenner, R. A., & Undheim, E. A. B. (2019) · Toxins · doi:10.3390/toxins11110666 · Cited by 285
“Consequently, toxins have been an important source of molecular tools for dissecting physiological processes [3], and lead molecules for the development of drugs targeting a range of conditions such as chronic pain [4], diabetes [5], cancer [6], stroke [7], and autoimmune disease [8].”
Peptide therapeutics from venom: Current status and potential
Pennington, M. W., Czerwinski, A., & Norton, R. S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.029 · Cited by 278
Antibodies and venom peptides: new modalities for ion channels
Wulff, H., Christophersen, P., Colussi, P., Chandy, K. G., & Yarov-Yarovoy, V. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0013-8 · Cited by 182
Animal toxins — Nature’s evolutionary-refined toolkit for basic research and drug discovery
Herzig, V., Cristofori-Armstrong, B., Israel, M. R., Nixon, S. A., Vetter, I., & King, G. F. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114096 · Cited by 181
Metadata
- Authors
- Tarcha, E. J., Olsen, C. M., Probst, P., Peckham, D., Muñoz-Elías, E. J., Kruger, J. G., & Iadonato, S. P.
- Affiliations
- Kineta (United States) (US)
- Rockefeller University (US)
- Corresponding author
- Olsen, Chelsea M.
- ORCID
- Olsen, Chelsea M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-07-19
- Volume
- 12
- Issue
- 7
- Pages
- e0180762
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5516987
- OpenAlex
- W2737389332
- Cited by
- 167
- References
- 48
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 25 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 18 · 2019: 20 · 2018: 13 · 2017: 6
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Keywords
- plaque psoriasis, memory T cells, drug safety, pharmacodynamics, numbness, paresthesia, inflammatory markers, T cell activation markers, PASI, subcutaneous injection
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Hypesthesia, Male, Middle Aged, Paresthesia, Proteins, Psoriasis, Treatment Outcome, Potassium Channel Blockers, Kv1.3 Potassium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.